MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer

Mohammad Alam Jafri, Syed Kashif Zaidi, Shakeel Ahmed Ansari, Mohammed Hussein Al-Qahtani, Jerry W. Shay

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: MicroRNAs (miRNAs) are small (19 - 22 nucleotide), non-protein-coding RNA segments that function as master regulators of hundreds of genes simultaneously in both normal and malignant cells. In colorectal cancer (CRC) miRNAs are deregulated and have critical roles in initiation and progression of CRC by interacting with various oncogenes and tumor suppressor genes including APC, KRAS and p53, or by modulating downstream signal transduction pathways. Numerous promising miRNAs have emerged as potential drug targets for therapeutic intervention and possible candidates for replacement therapy in CRC. Areas covered: In this review the authors summarize the available information on miRNAs and their role in CRC. The authors point out specific miRNAs as potential drug targets and those having a significant role in gene activation and gene silencing during the process of CRC development, to highlight their importance as possible therapeutic candidates for the treatment of CRC. Expert opinion: Targeting miRNAs provides an emerging opportunity to develop effective miRNA-based replacement therapy or antagonists to alter expression in colon cancer patient tumors. However, the biggest challenge is to overcome obstacles associated with pharmacokinetics, delivery and toxicity in order to translate the potential of miRNAs into efficacious anticancer drugs.

Original languageEnglish (US)
Pages (from-to)1705-1723
Number of pages19
JournalExpert Opinion on Therapeutic Targets
Volume19
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

MicroRNAs
Colorectal Neoplasms
Pharmaceutical Preparations
Genes
Therapeutics
Tumors
Signal transduction
Untranslated RNA
Pharmacokinetics
Expert Testimony
Gene Silencing
Regulator Genes
Tumor Suppressor Genes
Oncogenes
Colonic Neoplasms
Transcriptional Activation
Toxicity
Signal Transduction
Nucleotides
Chemical activation

Keywords

  • antagomirs
  • anti-microRNA oligonucleotides
  • colon cancer
  • genomic instability
  • microRNA dysregulation
  • microRNA mimics
  • microRNA silencing
  • replacement therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer. / Jafri, Mohammad Alam; Zaidi, Syed Kashif; Ansari, Shakeel Ahmed; Al-Qahtani, Mohammed Hussein; Shay, Jerry W.

In: Expert Opinion on Therapeutic Targets, Vol. 19, No. 12, 02.12.2015, p. 1705-1723.

Research output: Contribution to journalArticle

Jafri, Mohammad Alam ; Zaidi, Syed Kashif ; Ansari, Shakeel Ahmed ; Al-Qahtani, Mohammed Hussein ; Shay, Jerry W. / MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer. In: Expert Opinion on Therapeutic Targets. 2015 ; Vol. 19, No. 12. pp. 1705-1723.
@article{c9a53aec0f4d426db6ac6e85e4cc9243,
title = "MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer",
abstract = "Introduction: MicroRNAs (miRNAs) are small (19 - 22 nucleotide), non-protein-coding RNA segments that function as master regulators of hundreds of genes simultaneously in both normal and malignant cells. In colorectal cancer (CRC) miRNAs are deregulated and have critical roles in initiation and progression of CRC by interacting with various oncogenes and tumor suppressor genes including APC, KRAS and p53, or by modulating downstream signal transduction pathways. Numerous promising miRNAs have emerged as potential drug targets for therapeutic intervention and possible candidates for replacement therapy in CRC. Areas covered: In this review the authors summarize the available information on miRNAs and their role in CRC. The authors point out specific miRNAs as potential drug targets and those having a significant role in gene activation and gene silencing during the process of CRC development, to highlight their importance as possible therapeutic candidates for the treatment of CRC. Expert opinion: Targeting miRNAs provides an emerging opportunity to develop effective miRNA-based replacement therapy or antagonists to alter expression in colon cancer patient tumors. However, the biggest challenge is to overcome obstacles associated with pharmacokinetics, delivery and toxicity in order to translate the potential of miRNAs into efficacious anticancer drugs.",
keywords = "antagomirs, anti-microRNA oligonucleotides, colon cancer, genomic instability, microRNA dysregulation, microRNA mimics, microRNA silencing, replacement therapy",
author = "Jafri, {Mohammad Alam} and Zaidi, {Syed Kashif} and Ansari, {Shakeel Ahmed} and Al-Qahtani, {Mohammed Hussein} and Shay, {Jerry W.}",
year = "2015",
month = "12",
day = "2",
doi = "10.1517/14728222.2015.1069816",
language = "English (US)",
volume = "19",
pages = "1705--1723",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer

AU - Jafri, Mohammad Alam

AU - Zaidi, Syed Kashif

AU - Ansari, Shakeel Ahmed

AU - Al-Qahtani, Mohammed Hussein

AU - Shay, Jerry W.

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Introduction: MicroRNAs (miRNAs) are small (19 - 22 nucleotide), non-protein-coding RNA segments that function as master regulators of hundreds of genes simultaneously in both normal and malignant cells. In colorectal cancer (CRC) miRNAs are deregulated and have critical roles in initiation and progression of CRC by interacting with various oncogenes and tumor suppressor genes including APC, KRAS and p53, or by modulating downstream signal transduction pathways. Numerous promising miRNAs have emerged as potential drug targets for therapeutic intervention and possible candidates for replacement therapy in CRC. Areas covered: In this review the authors summarize the available information on miRNAs and their role in CRC. The authors point out specific miRNAs as potential drug targets and those having a significant role in gene activation and gene silencing during the process of CRC development, to highlight their importance as possible therapeutic candidates for the treatment of CRC. Expert opinion: Targeting miRNAs provides an emerging opportunity to develop effective miRNA-based replacement therapy or antagonists to alter expression in colon cancer patient tumors. However, the biggest challenge is to overcome obstacles associated with pharmacokinetics, delivery and toxicity in order to translate the potential of miRNAs into efficacious anticancer drugs.

AB - Introduction: MicroRNAs (miRNAs) are small (19 - 22 nucleotide), non-protein-coding RNA segments that function as master regulators of hundreds of genes simultaneously in both normal and malignant cells. In colorectal cancer (CRC) miRNAs are deregulated and have critical roles in initiation and progression of CRC by interacting with various oncogenes and tumor suppressor genes including APC, KRAS and p53, or by modulating downstream signal transduction pathways. Numerous promising miRNAs have emerged as potential drug targets for therapeutic intervention and possible candidates for replacement therapy in CRC. Areas covered: In this review the authors summarize the available information on miRNAs and their role in CRC. The authors point out specific miRNAs as potential drug targets and those having a significant role in gene activation and gene silencing during the process of CRC development, to highlight their importance as possible therapeutic candidates for the treatment of CRC. Expert opinion: Targeting miRNAs provides an emerging opportunity to develop effective miRNA-based replacement therapy or antagonists to alter expression in colon cancer patient tumors. However, the biggest challenge is to overcome obstacles associated with pharmacokinetics, delivery and toxicity in order to translate the potential of miRNAs into efficacious anticancer drugs.

KW - antagomirs

KW - anti-microRNA oligonucleotides

KW - colon cancer

KW - genomic instability

KW - microRNA dysregulation

KW - microRNA mimics

KW - microRNA silencing

KW - replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84951733168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951733168&partnerID=8YFLogxK

U2 - 10.1517/14728222.2015.1069816

DO - 10.1517/14728222.2015.1069816

M3 - Article

C2 - 26189482

AN - SCOPUS:84951733168

VL - 19

SP - 1705

EP - 1723

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 12

ER -